UBS began covering Ensysce Biosciences Inc (ENSC) with a Buy rating on November 12, 2026.
Two of two firms active in the past 90 days rate the stock in the bullish tier. As of November 6, 2026, four analysts place the consensus mean at $5.23, the median at $5.23 and the range at $2.02 to $8.66.
For Q4 FY2026, analysts expect EPS of -$0.10 and revenue of $1.22 million. The next earnings report is scheduled for November 12, 2026.
